# Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

> **NCT01010217** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 176 (actual)

## Conditions studied

- Blood Stem Cell Transplant Failure
- Leukemia
- Hematologic Malignancies

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Mesna
- **DRUG:** Rituximab
- **PROCEDURE:** Stem Cell Transplantation
- **DRUG:** Thiotepa
- **DRUG:** Tacrolimus
- **DRUG:** Mycofenolate mofetil
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT01010217
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-05
- **Primary completion:** 2017-10-05
- **Final completion:** 2017-10-05
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2020-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01010217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01010217, "Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01010217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*